

# Supporting continuous glucose monitoring for people with serious mental illness and type 2 diabetes: Protocol for a co-design study

Short title: Continuous glucose monitoring for people with serious mental illness and type 2 diabetes: co-design protocol

Jennifer VE Brown<sup>1\*</sup>, Ramzi Ajjan<sup>2</sup>, Najma Siddiqi<sup>1,3</sup>, Ian Kellar<sup>4</sup>, & Peter A Coventry<sup>1,5</sup>

## Author affiliations:

<sup>1</sup> Mental Health & Addiction Research Group, Department of Health Sciences, University of York, York, UK

<sup>2</sup> Division of Cardiovascular and Diabetes Research, School of Medicine, University of Leeds, Leeds, UK & Leeds Teaching Hospitals NHS Trust, Leeds, UK

<sup>3</sup> Hull York Medical School, York, UK & Bradford District Care NHS Foundation Trust, Bradford, UK

<sup>4</sup> Department of Psychology, Interdisciplinary Centre of the Social Sciences, University of Sheffield, Sheffield, UK

<sup>5</sup> York Environmental Sustainability Institute, University of York, York, UK

## Corresponding author:

Jennifer VE Brown, Mental Health & Addiction Research Group, Department of Health Sciences, University of York, York, UK; [jennifer.brown@york.ac.uk](mailto:jennifer.brown@york.ac.uk)

## 1 Abstract

## 2 Introduction

3 Compared with the general population, people with serious mental illness (SMI) are 2-3 times more  
4 likely to develop type 2 diabetes, have poorer outcomes, and die 15 to 20 years younger, often as a  
5 result of long-term physical health conditions. Standard diabetes care does not meet the needs of  
6 people with SMI and they are frequently excluded from research, missing out on innovation. As  
7 diabetes care increasingly uses technology like continuous glucose monitoring (CGM) it is important  
8 to consider the views of people with SMI when new interventions are developed. This is a study  
9 protocol to identify candidate components of a structured CGM intervention for people with SMI,  
10 including the co-design of a logic model and programme theory.

## 11 Methods

12 Drawing on experience-based co-design (EBCD) methods, we propose to collaborate with service-  
13 users, carers, and healthcare professionals to undertake early-phase development work for a novel  
14 intervention that maximises the potential of CGM to facilitate behaviour change. Fifteen participants  
15 will be recruited through existing cohorts and networks in England. The co-design will be informed  
16 by existing evidence and based on links between mechanisms of action and behaviour change  
17 techniques. Through a series of events (discovery sessions, co-design workshop, celebration event),  
18 we will identify candidate components for a prototype intervention ready for further development  
19 and testing. A logic model and programme theory will be developed and refined iteratively.

## 20 Discussion

21 The main output of this study will be a logic model and programme theory for a novel prototype  
22 intervention, ready for further testing following best practice intervention development, such as the  
23 Medical Research Council guidance for the development and evaluation of complex interventions.  
24 An intervention that makes CGM accessible for people with SMI has the potential to make a

25 considerable contribution to reducing the profound health inequalities experienced by this  
26 population.

27

28 **Study registration:** <https://osf.io/4ae3g/> (2<sup>nd</sup> February 2024)

29 **Key words:** co-design; intervention development; serious mental illness; type 2 diabetes; continuous  
30 glucose monitoring

31

## 32 Introduction

### 33 Serious mental illness and type 2 diabetes

34 People with serious mental illness (SMI), conditions like schizophrenia, bipolar disorder, or psychosis,  
35 are two to three times more likely to have type 2 diabetes than the general population.(1, 2, 3) The  
36 risk of diabetes complications and poorer outcomes is also increased.(4) Diabetes, alongside other  
37 long-term physical health conditions, contributes to a reduction in life expectancy by about 15 to 20  
38 years.(5) While this profound example of health inequality is well recognised internationally and is  
39 often called the “mortality gap”, attempts to “close the gap” have so far had limited success.(6)  
40 People with SMI continue to be less healthy and die earlier than the general population, with most  
41 early deaths caused by poor physical health, despite a growing number of research and policy  
42 initiatives aimed at reducing health inequalities among this population.

43 Additionally, people with SMI often miss out on healthcare innovation because they tend to be  
44 excluded from research studies.(7) As a group that engages differently with the healthcare system  
45 than the general population and frequently requires additional support to successfully access  
46 care,(8) people with SMI often do not benefit from existing interventions and services when they are  
47 offered without necessary adaptations.(9)

48 While self-management interventions for mental health have been found to be moderately  
49 effective,(10) diabetes self-management skills are often poorly developed among people with SMI;  
50 diabetes self-management is perceived as challenging,(11) and existing education programmes like  
51 DESMOND(12) do not address the additional needs arising from the dual challenge of managing  
52 diabetes alongside SMI.(13, 14)

### 53 [Advances in diabetes care through continuous glucose monitoring](#)

54 Technology plays an increasingly prominent role in diabetes care worldwide. Advances including  
55 continuous glucose monitoring (CGM) have introduced lasting changes not only to the delivery of  
56 care but also to the individual experience for people with diabetes.(15, 16, 17, 18, 19) CGM devices  
57 are two-part systems consisting of a body-worn sensor and an external reader (see Bruttomesso et  
58 al.(20) and Lin et al.(21) for an overview of available systems). CGM was introduced to simplify  
59 regular blood glucose monitoring. Recent systematic reviews confirm moderate levels of  
60 effectiveness of CGM in lowering glycated haemoglobin (HbA1c) in individuals with type 2  
61 diabetes(22) and those with type 1 diabetes.(23)

62 However, evidence of effectiveness is not observed universally.(24) A crucial discovery has been that  
63 glucose monitoring alone does not automatically lead to an improvement in diabetes management  
64 and a reduction in HbA1c.(24, 25) It is important to consider the context within which CGM is used.  
65 Glucose monitoring should be viewed as an intervention in itself, rather than merely a data  
66 collection tool.(26) Deployed on its own, i.e. without support and education for healthcare  
67 professionals (HCPs), the person with diabetes, and their carer(s), glucose monitoring is likely to be a  
68 waste of resource and studies continue to fail to show evidence of clinical effectiveness defined as a  
69 reduction in blood glucose.(27) There is growing evidence that structured glucose monitoring that  
70 includes “wrap-around” support, education, and feedback has the potential to improve diabetes  
71 management, lower HbA1c, and improve wider health and wellbeing outcomes, including quality of

72 life,(28, 29) pointing towards a synergistic effect of combining glucose monitoring with education  
73 and support.

74 While CGM is being rolled out to a growing population of children and adults with diabetes, people  
75 with SMI are not given special consideration,(30, 31) despite the potential of these devices to unlock  
76 engagement with the condition and the need to self-manage.(32) In the UK, people with SMI are  
77 offered an annual measurement of HbA1c as part of a wider physical health check and medication  
78 review in primary care.(33) However, beyond this annual check, people with SMI often struggle to  
79 access specialist diabetes care,(34) reinforcing inequities in the provision of care compared with the  
80 general population.

#### 81 [Including people with SMI in the future of CGM research](#)

82 Further research is warranted into how CGM might improve diabetes self-management and, in turn,  
83 glucose management and overall health and wellbeing, for people with SMI. This area is under-  
84 researched and the potential of CGM to facilitate behaviour change in this disadvantaged population  
85 remains untapped. Work is ongoing to test the effectiveness of a new co-designed supported  
86 diabetes self-management intervention for people with SMI.(35, 36, 37) However, while the  
87 DIAMONDS feasibility study included a test of the acceptability of CGM in a sample of 21 people with  
88 SMI, the sensors were not part of the intervention.

89 Our previous research has produced indicative findings that wearing a CGM sensor might be  
90 acceptable to people with SMI and that they may have an interest in seeing their data, which could  
91 be an initial step toward engaging with self-management. Qualitative findings suggest that increased  
92 awareness of their diabetes and the CGM sensor acting as a prompt might be key mechanisms that  
93 could be exploited as pathways to behaviour and lifestyle changes.

94 From previous work we also know that support with fitting the device as well as with the  
95 interpretation of the data will be crucial to maximise the chances of success. Similarly, our findings

96 suggest that HCPs involved in the care of people with SMI and diabetes will require tailored  
97 education depending on their professional background and expertise.

98 With the exception of SMI-specific studies, people with SMI continue to be largely excluded from  
99 health research, either explicitly through restricted eligibility criteria or implicitly through the use of  
100 methods that are inaccessible to this population.(7, 38, 39) For a vulnerable group with a  
101 disproportionately high illness burden who engage differently with healthcare than the general  
102 population and who do not tend to benefit from mainstream education and self-management  
103 interventions, this is clearly problematic. This study builds on our own findings as well as the limited  
104 existing evidence base about self-management of physical long-term conditions among people with  
105 SMI to take a more tailored approach that considers the needs of people with SMI. In this study, we  
106 propose to co-design a logic model and programme theory with service-users, carers, and HCPs for a  
107 structured CGM intervention for people with SMI.

## 108 [Theoretical foundations and guiding frameworks](#)

109 In line with best practice for the efficient design of evidence-based behaviour-change  
110 interventions,(40, 41) the intervention development process will be informed by existing evidence  
111 about mechanisms of action (MoAs)(42) and behaviour change techniques (BCTs)(43) that have been  
112 shown to be effective in self-management interventions. The Theory and Techniques Tool offers a  
113 systematic approach to linking MoAs and BCTs,(44) an approach that has previously been employed  
114 in the context of SMI and diabetes self-management as shown in the development of the  
115 DIAMONDS intervention.(37)

116 This co-design study is situated within a context of existing interventions, including CGM itself and  
117 the DIAMONDS self-management intervention. However, the ambition is to develop a logic model  
118 and programme theory for a new, bespoke intervention that addresses specifically the lack of CGM  
119 support and education that has been co-designed and is accessible to people with SMI. As such, this  
120 study sets out to co-design a novel intervention rather than an adapt an existing one.(45) Broadly,

121 we will follow the Medical Research Council guidance for the development and evaluation of  
122 complex interventions(40) whilst also drawing on principles of multiphase optimisation strategy in  
123 determining candidate intervention components ready for further testing.(46)

124 This protocol is reported in line with GUIDED (GUIDance for the rEporting of intervention  
125 Development),(47) with a completed checklist included in Appendix 1.

## 126 Target population, study aim, and objectives

127 The target population for the new intervention are adults (aged 18 years or over) living in the  
128 community with confirmed diagnoses of both type 2 diabetes and SMI (schizophrenia,  
129 schizoaffective disorder, psychosis, bipolar disorder, severe depression).

130 Building on existing evidence in the general population, and feasibility testing and qualitative  
131 research that suggests acceptability of CGM in people with SMI, we propose to co-design with  
132 service users, carers, and healthcare professionals (HCPs) a logic model and programme theory that  
133 include candidate components for a structured CGM intervention. Specifically, we will address the  
134 following objectives:

- 135 1. To identify candidate intervention components from existing evidence, including the  
136 identification of BCTs and MoAs
- 137 2. To establish consensus on candidate components of structured CGM from service users and  
138 carers
- 139 3. To establish consensus on candidate components of structured CGM from HCPs
- 140 4. To synthesise outputs from objectives 1 to 3 to develop a preliminary logic model and  
141 programme theory

142 It is not within the scope of this study to include technical innovations in the refinement or further  
143 development of CGM devices or systems.

## 144 Methods

145 We will undertake an accelerated co-design study of candidate intervention components, drawing  
146 on established experience-based co-design (EBCD) methods(48) as well as other knowledge  
147 translation strategies that have been shown to support co-design.(49) The project will involve the  
148 following steps:

- 149 1) Synthesis of existing evidence
- 150 2) Discovery session with service-users and carers
- 151 3) Discovery session with HCPs
- 152 4) Reflection and synthesis
- 153 5) Joint co-design event with breakout groups, including service-users, carers, and HCPs
- 154 6) Synthesis and prototyping
- 155 7) Joint showcase and celebration, including service-users, carers, and HCPs

## 156 The project team

157 The project will be led by JB, a behaviour change researcher with a background in health psychology  
158 and experience in applied health research. JB will be supported by PC, RA, IK, and NS who are senior  
159 researchers with expertise in health services research, diabetes, health psychology, and psychiatry,  
160 respectively. In addition, a member of an established service-user and carer group will be a part of  
161 the project team, contributing lived experience of SMI and diabetes. The project will be supported  
162 by a trained independent facilitator.(50)

## 163 Participants

164 We will recruit three groups of participants to take part in this study: service-users, carers, and HCPs.  
165 Our aim is to have equal representation of each group, and we will strive to recruit five service-  
166 users, five carers, and five HCPs (total N=15). Service-users and carers will be recruited from existing  
167 cohorts of participants from previous studies who have given consent to be recontacted about



168 future research opportunities. In addition, participating service-users will be asked to identify  
 169 informal carers who may be interested in taking part. We are using the King’s Fund definition(51) of  
 170 informal carers which has been adopted by the NHS and Department of Health and Social Care and  
 171 includes anyone looking after “*a relative or friend who needs support because of ... illness, including*  
 172 *mental illness*”, offering “*active support, supervision, or social interaction*”. HCPs will be recruited  
 173 from existing networks and contacts, using a snowballing approach to building a diverse sample that  
 174 includes practitioners with expertise in mental health care, such as psychiatrists or mental health  
 175 nurses, as well as diabetes care, like diabetologists, endocrinologists, or specialist nurses. In addition,  
 176 we will recruit primary care professionals, i.e. general practitioners (GPs) or practice nurses. We will  
 177 not restrict participation by role, job title, or seniority. Appendix 2 describes the recruitment and  
 178 consent process in detail, including examples of the participant-facing documents.

179 Eligibility criteria

180 Table 1 summarises the eligibility criteria for the three groups of participants described above.

181 *Table 1: Eligibility criteria for participation.*

	<b>Inclusion</b>	<b>Exclusion</b>
<b>All participants</b>		
<i>Age</i>	18 years or older	Under 18 years
<i>Capacity</i>	Capacity to consent	No capacity to consent
<i>Cognitive impairment</i>	No or mild cognitive impairments no affecting ability to provide informed consent.	Any cognitive impairment that affects ability to provide informed consent.
<i>Language<sup>1</sup></i>	Ability to communicate in spoken English.	No or severely limited ability to communicate in spoken English, e.g. requiring the use of an interpreter.
<i>Time commitment<sup>2</sup></i>	Commitment to attending and contributing to at least two out of three sessions (discovery session, co-design workshop, celebration event).	Not able to commit to at least two out of three sessions.
<b>Additional criteria for service-users</b>		
<i>SMI diagnosis</i>	At least 1 of the following <ul style="list-style-type: none"> <li>• Schizophrenia</li> <li>• Schizoaffective disorder</li> <li>• Bipolar disorder</li> <li>• Psychosis</li> </ul>	<ul style="list-style-type: none"> <li>• Any other mental health diagnosis, regardless of severity or duration.</li> <li>• No mental health diagnosis.</li> </ul>

	<ul style="list-style-type: none"> <li>Severe depression</li> </ul> <p>Patients with or without other co-occurring mental health conditions are eligible.</p>	
<i>Diabetes diagnosis</i>	<p>Type 2 diabetes (insulin-treated or non-insulin-treated).</p> <p>Patients with or without other co-occurring physical health conditions are eligible.</p>	<p>Any other type of diabetes, including</p> <ul style="list-style-type: none"> <li>Gestational diabetes</li> <li>Type 1 diabetes</li> <li>Diabetes secondary to other health conditions, e.g. genetic defects</li> </ul>
<i>Living situation</i>	<ul style="list-style-type: none"> <li>Community dwelling</li> <li>Living in supported housing or residential settings with some degree of autonomy over day-to-day activities</li> </ul>	Current inpatients
<b>Additional criteria for carers</b>		
<i>Caring responsibilities</i>	<p>Current or recent unpaid carer of a person meeting the criteria outlined above for service-user participants, e.g. a family member, spouse, or friend.</p> <p>Carers are eligible to take part regardless of whether the person they care for (service-user) is taking part in the study.</p>	<ul style="list-style-type: none"> <li>Paid, i.e. professional, carers.</li> <li>Family members, spouses, or friends of service-users who do not provide care.</li> </ul>
<b>Additional criteria for HCPs</b>		
<i>HCP role and experience</i>	<p>Any HCP, regardless of job role or seniority, with current or recent experience in at least one of the following:</p> <ul style="list-style-type: none"> <li>Primary care, e.g. annual physical health checks for people with SMI</li> <li>Mental health care delivered in community-based secondary care settings for people with SMI, e.g. clozapine clinics, community mental health teams, early intervention psychosis clinics</li> <li>Diabetes care delivered in secondary care settings, e.g. diabetes clinics</li> </ul>	<p>Any other HCP, including</p> <ul style="list-style-type: none"> <li>Mental health professionals without direct experience working with people with SMI</li> <li>Mental health professional working exclusively with inpatients</li> <li>HCPs from any specialty not relevant to mental health or diabetes.</li> </ul>

182 <sup>1</sup>*Language:* We will not formally assess prospective participants' level of English, but a sufficient grasp of the  
183 language is crucial for participation in this study. Where possible, we will make adjustments, for example by  
184 reading aloud study information materials and limiting the amount of reading and writing participants are  
185 asked to do.

186 <sup>2</sup>*Time commitment:* Participants will have the right to stop their participation at any point and without having  
187 to provide a reason. However, at the point of recruitment, prospective participants will be informed that  
188 participation involves attendance at three events, and they will be encouraged to commit to attending at least

189 two out of the three. This is to ensure continuity of participants across the study and to minimise the need for  
190 recruitment of additional participants partway through the project. We will aim to over-recruit participants  
191 from all three groups to mitigate against the risk of low attendance.

## 192 [Project plan](#)

### 193 [Step 1: Synthesis of existing evidence](#)

194 Findings from a recent mixed-methods systematic review of the acceptability and feasibility of CGM  
195 in people with diabetes(52) that have been analysed within the Theoretical Framework of  
196 Acceptability (TFA)(53) will be interrogated further using the Theory and Techniques Tool linking  
197 BCTs and associated MoAs (i.e., short-term outcomes). In particular, we will extract detail from  
198 included studies that describe a structured CGM intervention, i.e. the use of “wrap-around”  
199 education and support. In addition, we will draw on findings from a mixed-methods feasibility study  
200 of using CGM in a population of people with type 2 diabetes and SMI which have also been analysed  
201 and synthesised using the TFA. This will include a description of the CGM systems available in the UK  
202 as well as an explanation of different ways of accessing glucose data.

203 We will complement this evidence with key findings from other programmes of research looking to  
204 improve the physical health of people with SMI, particularly those that include the use of technology  
205 in their interventions, e.g. DIAMONDS(37) and Stepwise.(54)

206 To mobilise the synthesised evidence base for the participants in our study, we will develop an  
207 animated catalyst film, a number of fictional personas, and descriptions of MoAs and BCTs in  
208 accessible language, contextualised for use in the discovery sessions and co-design event.

### 209 [Steps 2 & 3: Discovery sessions](#)

210 We will conduct separate discovery sessions with different groups of participants. Independently,  
211 people with SMI and type 2 diabetes and their informal carers (group 1) and HCPs (group 2) will be  
212 asked to use existing evidence to stimulate rapid idea generation for candidate intervention  
213 components and content:

- 214 1. **Catalyst film:** This short animation will present fictional characters in situations that are  
215 likely to be familiar to participants, e.g. challenges in navigating the healthcare system or  
216 difficulties engaging with physical health self-management
- 217 2. **Personas:** The characters from the catalyst film will additionally be presented as personas  
218 that are designed to resonate with participants and their own experiences.
- 219 3. **Journey mapping/pain point analysis:** We will work with participants to understand the key  
220 barriers (“pain points”) in the patient journey using the personas, i.e. their pathway through  
221 the healthcare system within which they are seeking support.
- 222 4. **Prototyping:** We will provide accessible minimal viable prototype paper-based BCTs for  
223 participants to cluster to pain points and comment on.

224 Throughout the session, materials will be presented to participants to facilitate discussion and the  
225 generation of ideas. Participants will be encouraged to go beyond, add to, and contradict the  
226 presented materials. In the synthesis sessions, new content provided by participants will be  
227 prioritised. All ideas generated in the discovery sessions will be captured through note taking during  
228 discussions as well as photographs of any written outputs, such as flipcharts or sticky notes.

#### 229 Step 4: Reflection and synthesis

230 Outputs from the discovery sessions relating to the acceptability of CGM will be coded against the  
231 TFA for further discussion in step 5 (joint co-design session). Those outputs that relate more directly  
232 to BCTs and/or MoAs will be integrated with the initial mapping framework that was produced in  
233 step 1.

234 The main objective of the synthesis and reflection phase will be to produce expanded examples of  
235 possible intervention components, highlighting the links between BCTs and MoAs. This will be  
236 informed by the evidence synthesised in step 1 as well as outputs from steps 2 and 3.

237 To support knowledge mobilisation, at this stage we will develop an accessible logic model in lay  
238 language alongside a logic model that uses the formal BCT/MoA language which will illustrate

239 putative mechanisms between potential intervention components while also capturing the role of  
240 the context within which the intervention is likely to be situated.

#### 241 Step 5: Joint co-design event with breakout groups

242 For this session, all participants (service-users, carers, and HCPs) will work together with the  
243 research team. The focus will be on reaching consensus about key BCTs through joint prioritisation.

244 Mirroring the approach used in steps 2 and 3, some materials will be presented to participants to  
245 enable informed and concentrated conversations. As before, participants will be encouraged to  
246 expand on and move beyond these initial prompts.

247 Initially, participants will be presented with the outputs from the reflection and synthesis stage, i.e.  
248 examples of BCT/MoA links and how they might fit within a draft logic model. There will be a chance  
249 for participants to add further BCTs (intervention components) that they feel are missing. The final  
250 list will then be subject to a prioritisation exercise whereby participants will work individually or in  
251 small groups (depending on preference) to rank the BCTs in order of importance.

252 The most important BCTs will be developed further, e.g. through sketching, prototyping, or in the  
253 form of written comments.

#### 254 Step 6: Synthesis and prototyping

255 As previously, the research team will meet after the co-design event to summarise and synthesise  
256 outputs. At this stage, the focus will be on the integration of the expanded BCT/MoAs links from step  
257 5 into the draft logic model and programme theory. The aim of this synthesis stage is to produce a  
258 plain language, easily accessible description of what a structured CGM intervention may look like.

#### 259 Step 7: Joint showcase and celebration

260 The focus of this final event will be to share the intervention prototype and to acknowledge and  
261 celebrate the contributions of all participants in the development process. After the initial  
262 presentation of the prototype, there will be a chance for further discussion and feedback, this will be

263 free flowing rather than the structured workshop format of the previous sessions. Any pertinent  
264 points will be recorded and considered for inclusion for the next stages after completion of this  
265 study.

## 266 [Decision making priorities and guiding principles](#)

267 Throughout the project, we will aim to prioritise service-user and carer views and perspectives.  
268 However, we acknowledge the need for pragmatism and compromise while operating within time  
269 and funding constraints. To ensure that the amount of session content is manageable, reflection and  
270 synthesis meetings will be used to prioritise items for discussion. Where there are differences of  
271 opinion between the three groups of participants, we will aim to explore those in discussion at the  
272 subsequent sessions to reach a deeper understanding and, wherever possible, a mutually acceptable  
273 compromise.

274 Disagreements between participant preferences and published evidence will be addressed in a  
275 collaborative fashion with the aim of finding a way to include the published evidence in the  
276 intervention in such a way that is acceptable to service users, carers, and HCPs. Conflicting ideas can  
277 also be captured in the design of the candidate intervention components and explored in future  
278 evaluation.

## 279 [Responsible research and innovation \(RRI\)](#)

280 Appendix 3 summarises our consideration of equity, diversity, and inclusion in this project as well as  
281 reflections on expected participant burden and our plans for participant recognition.

## 282 [Study management](#)

283 Information about study management, governance, and data protection, as well as participant and  
284 researcher safety and wellbeing can be found in Appendix 4.

## 285 Knowledge translation and pathways to impact

286 The main output from this study will be a programme theory and logic model for a structured CGM  
287 intervention for people with SMI ready for further testing and refinement. Building on the  
288 programme theory, the next step will be to develop a co-designed intervention that addresses the  
289 needs of service-users and carers, including training materials for facilitators. This intervention will  
290 then need to be further refined and optimised through testing of acceptability and feasibility prior to  
291 definitive evaluation.

292 We will work in an iterative, rather than linear, fashion to avoid premature progression to efficacy  
293 and effectiveness testing if further intervention development or refinement work is needed. If the  
294 composition of the new intervention allows, we will consider a multi-phase optimisation strategy  
295 (MOST) approach which would enable us to understand the contribution of each intervention  
296 component as well as any interactions between them.(55) We will continue to collaborate with  
297 service users, carers, as well as HCPs to refine the logic model for the new intervention which will  
298 inform the design of further studies.

## 299 Discussion

300 The proposed study will draw together evidence about the acceptability and feasibility of CGM in the  
301 general population with diabetes, about diabetes self-management among people with SMI, and  
302 emerging findings about the ways CGM might influence behaviour. Guided by established links  
303 between MoAs and BCTs, as per the Theory and Techniques tool, we will work with service-users,  
304 carers, and HCPs to build on these foundations and co-design a programme theory and logic model  
305 for a structured CGM intervention. The study will take a collaborative approach throughout, and  
306 service user and carer perspectives will be foregrounded.

307 The proposed study is situated within a context where we know little about CGM use, uptake, or  
308 effectiveness among people with SMI. A recent trial-based cohort study of 279 adults with type 2

309 diabetes in Australia using CGM, revealed a 1.4% prevalence of schizophrenia/bipolar disorder  
310 (4/279 participants). Understandably, due to the very small numbers, no correlation was reported  
311 between glycaemic measures, including HbA1c and time-in-range, and SMI.(56) In CGM research as  
312 in diabetes care the specific focus on SMI is often lacking and considerations of mental health rarely  
313 extend beyond common mental disorders or diabetes distress. However, the importance of  
314 behavioural and contextual factors is recognised increasingly as crucial in shaping the future of  
315 diabetes care, especially for type 2 diabetes.(57) For example, Hermanns et al. (2022)(58) argue that  
316 the integration of behavioural, psychological, and glycaemic data could be key in the drive towards  
317 precision medicine in diabetes care by supporting personalised and real-time treatment adjustments  
318 and changes to care. They suggest that this might also be true for people with bipolar disorder or  
319 depression whereby monitoring could predict relapses which could be avoided with early  
320 intervention, consequently leading to an avoidance of deteriorating glucose values. Whether or not  
321 this is feasible in practice is unclear at this stage. Firstly, changes in physical activity may be difficult  
322 to detect among people with SMI who tend to have extremely sedentary lifestyles.(59) Secondly,  
323 people with SMI may not consent to the intensive ongoing monitoring and the use of Artificial  
324 Intelligence for this kind of precision-focused approach.(60)

325 Innovative work by Lee et al. (2023)(61) highlights the challenges that arise from the growing  
326 complexity when different data sources, types, and measurements are combined to deliver more  
327 personalised diabetes care. In their three-arm RCT they compared treatment as usual (group A), with  
328 use of a digital integrated healthcare platform (group B), and with use of the data platform,  
329 feedback from HCPs, and intermittent CGM (group C). Both groups B and C showed lower HbA1c and  
330 greater weight loss at follow-up compared with group A. Group C showed greater improvements  
331 than group B, but these did not reach statistical significance. The intervention received by group C  
332 was so complex that it is impossible to unpick from the outcome data alone which component(s)  
333 made the difference beyond the data platform and, indeed, if individual components acted  
334 antagonistically and cancelled each other out.



335 The current state of the evidence supports the notion that targeted work in collaboration with  
336 people with SMI is very much needed.(57) In a commentary on Lee et al., Kahkoska and colleagues  
337 (2023)(62) propose four priorities to maximise the potential of technology-enhanced behaviour-  
338 change interventions that are applicable across the population of people with type 2 diabetes,  
339 including those who also have SMI. Kahkoska et al. suggest that equity, personalisation, integration  
340 with health services, and rigorous evaluation will be crucial going forward. The work proposed here  
341 very much aligns with these priorities.

342 The new intervention will have the potential to address profound health inequalities by improving  
343 diabetes care for people with SMI who face higher risks, poorer outcomes, and reduced life  
344 expectancy. Current care is clearly not meeting the needs of this vulnerable population; making CGM  
345 accessible in a scalable fashion has tremendous potential to improve the lives of some of the most  
346 disadvantaged in society. Evidence from a cohort of 813 children with type 1 diabetes suggest that  
347 CGM partially mediated the considerable inequalities that are observed in correlations between  
348 socioeconomic status and glycaemic management, where those from more deprived areas tend to  
349 show poorer management.(63) Exploring the potential of CGM to close, or at least narrow, the  
350 mortality gap is imperative and there is no reason to assume that the same mediating effect might  
351 not be observed among adults with type 2 diabetes, where similar patterns of inequalities are  
352 evident.(64, 65)

### 353 Conclusions

354 There is a clear need for the development of an intervention that supports people with SMI to  
355 benefit from CGM. Co-design has been shown to produce highly acceptable interventions and upon  
356 development of a programme theory and logic model we expect to be in a strong position to  
357 develop a novel intervention that has the potential to address profound inequalities.

358

## References

1. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RIG, Möller HJ. Cardiovascular disease and diabetes in people with severe mental illness. Position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). *European Psychiatry*. 2009;24:412-24.
2. Reilly S, Olier I, Planner C, Doran T, Reeves D, Ashcroft DM, et al. Inequalities in physical comorbidity: a longitudinal comparative cohort study of people with severe mental illness in the UK. *BMJ Open*. 2015;5(12):e009010.
3. Stubbs B, Vancampfort D, De Hert M, Mitchell AJ. The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis. *Acta Psychiatrica Scandinavica*. 2015;132(2):144-57.
4. Scheuer SH, Kosjerina V, Lindekilde N, Pouwer F, Carstensen B, Jørgensen ME, et al. Severe Mental Illness and the Risk of Diabetes Complications: A Nationwide, Register-based Cohort Study. *The Journal of Clinical Endocrinology & Metabolism*. 2022;107(8):e3504-e14.
5. National Mental Health Intelligence Network. Premature mortality in adults with severe mental illness (SMI). 2023.
6. Siddiqi N, Doran T, Prady SL, Taylor J. Closing the mortality gap for severe mental illness: Are we going in the right direction? *The British Journal of Psychiatry*. 2017;211(3):130-1.
7. Harris JI, Hanson D, Leskela J, Billig J, Padilla-Martinez V, Boyd J, et al. Reconsidering research exclusion for serious mental illness: Ethical principles, current status, and recommendations. *Journal of Psychiatric Research*. 2021;143:138-43.
8. Mercer SW, Gunn J, Bower P, Wyke S, Guthrie B. Managing patients with mental and physical multimorbidity. *BMJ : British Medical Journal*. 2012;345:e5559.
9. Zabell V, Arnfred SM, Rønne ST, Berring LL, Lerbæk B, Jørgensen R. Combining diabetes and mental health care: An ethnographic exploration of user involvement in combined care. *Journal of Clinical Nursing*. 2023;32(17-18):6622-33.
10. Lean M, Fornells-Ambrojo M, Milton A, Lloyd-Evans B, Harrison-Stewart B, Yesufu-Udechuku A, et al. Self-management interventions for people with severe mental illness: systematic review and meta-analysis. *The British Journal of Psychiatry*. 2019;214(5):260-8.
11. Smith R, Han L, Ali S, Prady SL, Taylor J, Hughes T, et al. Glucose, cholesterol and blood pressure in type II diabetes: A longitudinal observational study comparing patients with and without severe mental illness. *J Psychiatr Ment Health Nurs*. 2019;26(9-10):347-57.
12. Leicester Diabetes Centre at University Hospitals of Leicester NHS Trust. DESMOND 2020 [cited 2023 27 November]. Available from: <https://www.desmond.nhs.uk/>.
13. Roberts SH, Bailey JE. An ethnographic study of the incentives and barriers to lifestyle interventions for people with severe mental illness. *J Adv Nurs*. 2013;69(11):2514-24.
14. Aschbrenner K, Carpenter-Song E, Mueser K, Kinney A, Pratt S, Bartels S. A qualitative study of social facilitators and barriers to health behavior change among persons with serious mental illness. *Community Ment Health J*. 2013;49(2):207-12.
15. Funtanilla VD, Candidate P, Caliendo T, Hilas O. Continuous Glucose Monitoring: A Review of Available Systems. *P T*. 2019;44(9):550-3.
16. Beck RW, Bergenstal RM, Cheng P, Kollman C, Carlson AL, Johnson ML, et al. The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1c. *Journal of Diabetes Science and Technology*. 2019;13(4):614-26.
17. Malandrucio I, Russo B, Picconi F, Menduni M, Frontoni S. Glycemic Status Assessment by the Latest Glucose Monitoring Technologies. *International Journal of Molecular Sciences*. 2020;21(21):8243.
18. Chen C, Zhao X-L, Li Z-H, Zhu Z-G, Qian S-H, Flewitt AJ. Current and Emerging Technology for Continuous Glucose Monitoring. *Sensors*. 2017;17(1):182.
19. Cappon G, Vettoretti M, Sparacino G, Facchinetti A. Continuous Glucose Monitoring Sensors for Diabetes Management: A Review of Technologies and Applications. *Diabetes Metab J*. 2019;43(4):383-97.
20. Bruttomesso D, Laviola L, Avogaro A, Bonora E, Del Prato S, Frontoni S, et al. The use of real time continuous glucose monitoring or flash glucose monitoring in the management of diabetes: A consensus view of Italian diabetes experts using the Delphi method. *Nutrition, Metabolism and Cardiovascular Diseases*. 2019;29(5):421-31.
21. Lin R, Brown F, James S, Jones J, Ekinci E. Continuous glucose monitoring: A review of the evidence in type 1 and 2 diabetes mellitus. *Diabetic Medicine*. 2021;n/a(n/a):e14528.

22. Uhl S, Choure A, Rouse B, Loblack A, Reaven P. Effectiveness of Continuous Glucose Monitoring on Metrics of Glycemic Control in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials. *J Clin Endocrinol Metab.* 2023.
23. Teo E, Hassan N, Tam W, Koh S. Effectiveness of continuous glucose monitoring in maintaining glycaemic control among people with type 1 diabetes mellitus: a systematic review of randomised controlled trials and meta-analysis. *Diabetologia.* 2022;65(4):604-19.
24. Malanda UL, Welschen LMC, Riphagen, II, Dekker JM, Nijpels G, Bot SDM. Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin. *Cochrane Database of Systematic Reviews.* 2012(1).
25. Lim S, Kang SM, Kim KM, Moon JH, Choi SH, Hwang H, et al. Multifactorial intervention in diabetes care using real-time monitoring and tailored feedback in type 2 diabetes. *Acta Diabetologica.* 2016;53(2):189-98.
26. Wright EE, Subramanian S. Is Continuous Glucose Monitoring a Tool, an Intervention, or Both? *Diabetes Technology & Therapeutics.* 2023;25(S3):S-48-S-55.
27. Polonsky WH, Fisher L. Self-Monitoring of Blood Glucose in Noninsulin-Using Type 2 Diabetic Patients: Right answer, but wrong question: self-monitoring of blood glucose can be clinically valuable for noninsulin users. *Diabetes Care.* 2012;36(1):179-82.
28. Polonsky WH, Fisher L, Schikman CH, Hinnen DA, Parkin CG, Jelsovsky Z, et al. Structured Self-Monitoring of Blood Glucose Significantly Reduces A1C Levels in Poorly Controlled, Noninsulin-Treated Type 2 Diabetes: Results from the Structured Testing Program study. *Diabetes Care.* 2011;34(2):262-7.
29. Polonsky WH, Fisher L. When Does Personalized Feedback Make A Difference? A Narrative Review of Recent Findings and Their Implications for Promoting Better Diabetes Self-Care. *Current Diabetes Reports.* 2015;15(8):50.
30. National Institute for Health and Clinical Excellence (NICE). Guideline: Type 1 diabetes in adults: diagnosis and management. Draft for consultation 2021 [cited 2021 5 December]. Available from: <https://www.nice.org.uk/guidance/GID-NG10265/documents/draft-guideline>.
31. National Institute for Health and Clinical Excellence (NICE). Guideline: Type 2 diabetes in adults: management. Draft for consultation 2021 [cited 2021 5th December]. Available from: <https://www.nice.org.uk/guidance/GID-NG10264/documents/draft-guideline>.
32. Zheng Y, Campbell Rice B, Melkus GDE, Sun M, Zweig S, Jia W, et al. Dietary Self-Management Using Mobile Health Technology for Adults With Type 2 Diabetes: A Scoping Review. *Journal of Diabetes Science and Technology.* 2023;17(5):1212-25.
33. Barnes TRE, MacCabe JH, Kane JM, Delgado O, Paton C. The physical health and side-effect monitoring of patients prescribed clozapine: data from a clinical audit conducted in UK mental health services. *Ther Adv Psychopharmacol.* 2020;10:2045125320937908.
34. McBain H, Lamontagne-Godwin F, Haddad M, Simpson A, Chapman J, Jones J, et al. Management of type 2 diabetes mellitus in people with severe mental illness: an online cross-sectional survey of healthcare professionals. *BMJ Open.* 2018;8(2):e019400.
35. The DIAMONDS Research Team. DIAMONDS: Improving diabetes self-management and outcomes for people with severe mental illness 2023 [cited 2023 18th August]. Available from: <https://www.diamondscollaboration.org.uk/>.
36. The DIAMONDS Research Team. Improving diabetes self-management for people with severe mental illness 2022 [cited 2023 18th August]. Available from: <https://www.isrctn.com/ISRCTN22275538>.
37. Carswell C, Coventry PA, Brown JVE, Alderson SL, Double K, Gilbody S, et al. Development of a Supported Self-management Intervention for People With Severe Mental Illness and Type 2 Diabetes: Theory and Evidence-Based Co-design Approach. *J Med Internet Res.* 2023;25:e43597.
38. Tranberg K, Due TD, Rozing M, Jønsson ABR, Kousgaard MB, Møller A. Challenges in reaching patients with severe mental illness for trials in general practice—a convergent mixed methods study based on the SOFIA pilot trial. *Pilot and Feasibility Studies.* 2023;9(1):182.
39. Kanuch SW, Cassidy KA, Dawson NV, Athey M, Fuentes-Casiano E, Sajatovic M. Recruiting and Retaining Individuals with Serious Mental Illness and Diabetes in Clinical Research: Lessons Learned from a Randomized, Controlled Trial. *J Health Dispar Res Pract.* 2016;9(3):115-26.
40. Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, et al. A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance. *BMJ.* 2021;374:n2061.
41. Rothman AJ. "Is there nothing more practical than a good theory?": Why innovations and advances in health behavior change will arise if interventions are used to test and refine theory. *International Journal of Behavioral Nutrition and Physical Activity.* 2004;1(1):11.

42. Carey RN, Connell LE, Johnston M, Rothman AJ, de Bruin M, Kelly MP, et al. Behavior Change Techniques and Their Mechanisms of Action: A Synthesis of Links Described in Published Intervention Literature. *Ann Behav Med*. 2019;53(8):693-707.
43. Michie S, Richardson M, Johnston M, Abraham C, Francis J, Hardeman W, et al. The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: building an international consensus for the reporting of behavior change interventions. *Ann Behav Med*. 2013;46(1):81-95.
44. Johnston M, Carey RN, Connell Bohlen LE, Johnston DW, Rothman AJ, de Bruin M, et al. Development of an online tool for linking behavior change techniques and mechanisms of action based on triangulation of findings from literature synthesis and expert consensus. *Translational Behavioral Medicine*. 2020;11(5):1049-65.
45. Moore G, Campbell M, Copeland L, Craig P, Movsisyan A, Hoddinott P, et al. Adapting interventions to new contexts—the ADAPT guidance. *BMJ*. 2021;374:n1679.
46. Guastaferrero K, Pfammatter AF. Guidance on selecting a translational framework for intervention development: Optimizing interventions for impact. *Journal of Clinical and Translational Science*. 2023;7(1):e119.
47. Duncan E, O’Cathain A, Rousseau N, Croot L, Sworn K, Turner KM, et al. Guidance for reporting intervention development studies in health research (GUIDED): an evidence-based consensus study. *BMJ Open*. 2020;10(4):e033516.
48. Locock L, Robert G, Boaz A, Vougioukalou S, Shuldham C, Fielden J, et al. Health Services and Delivery Research. Testing accelerated experience-based co-design: a qualitative study of using a national archive of patient experience narrative interviews to promote rapid patient-centred service improvement. Southampton (UK): NIHR Journals Library; 2014.
49. Grindell C, Coates E, Croot L, O’Cathain A. The use of co-production, co-design and co-creation to mobilise knowledge in the management of health conditions: a systematic review. *BMC Health Services Research*. 2022;22(1):877.
50. Clarke D, Gombert-Waldron K, Honey S, Cloud G, Harris R, Macdonald A, et al. Co-designing organisational improvements and interventions to increase inpatient activity in four stroke units in England: a mixed-methods process evaluation using normalisation process theory. *BMJ Open*. 2021;11(1):e042723.
51. The King’s Fund. *Informal Care in England*. 2006.
52. Brown JVE, Coventry P, Siddiqi N, Ajjan R. Acceptability and feasibility of continuous glucose monitoring in people with diabetes: protocol for a mixed-methods systematic review of quantitative and qualitative evidence 2021 [Available from: [https://www.crd.york.ac.uk/prospero/display\\_record.php?RecordID=255141](https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=255141)].
53. Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. *BMC Health Services Research*. 2017;17(1):88.
54. Holt RIG, Gossage-Worrall R, Hind D, Bradburn MJ, McCrone P, Morris T, et al. Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial. *Br J Psychiatry*. 2019;214(2):63-73.
55. Collins LM, Murphy SA, Strecher V. The multiphase optimization strategy (MOST) and the sequential multiple assignment randomized trial (SMART): new methods for more potent eHealth interventions. *Am J Prev Med*. 2007;32(5 Suppl):S112-8.
56. Chiang JI, Manski-Nankervis J-A, Thuraingam S, Jenkins A, O’Neal D, Mair FS, et al. Multimorbidity, glycaemic variability and time in target range in people with type 2 diabetes: A baseline analysis of the GP-OSMOTIC trial. *Diabetes Research and Clinical Practice*. 2020;169:108451.
57. Kremers SHM, Wild SH, Elders PJM, Beulens JWJ, Campbell DJT, Pouwer F, et al. The role of mental disorders in precision medicine for diabetes: a narrative review. *Diabetologia*. 2022;65(11):1895-906.
58. Hermanns N, Ehrmann D, Shapira A, Kulzer B, Schmitt A, Laffel L. Coordination of glucose monitoring, self-care behaviour and mental health: achieving precision monitoring in diabetes. *Diabetologia*. 2022;65(11):1883-94.
59. Bort-Roig J, Briones-Buixassa L, Felez-Nobrega M, Guàrdia-Sancho A, Sitjà-Rabert M, Puig-Ribera A. Sedentary behaviour associations with health outcomes in people with severe mental illness: a systematic review. *Eur J Public Health*. 2020;30(1):150-7.
60. Brunette MF, Achtyes E, Pratt S, Stilwell K, Opperman M, Guarino S, et al. Use of Smartphones, Computers and Social Media Among People with SMI: Opportunity for Intervention. *Community Ment Health J*. 2019;55(6):973-8.
61. Lee Y-B, Kim G, Jun JE, Park H, Lee WJ, Hwang Y-C, et al. An Integrated Digital Health Care Platform for Diabetes Management With AI-Based Dietary Management: 48-Week Results From a Randomized Controlled Trial. *Diabetes Care*. 2023;46(5):959-66.
62. Kahkoska AR, Cristello Sarteau A, Crowley MJ. Delivering on the Promise of Technology to Augment Behavioral Interventions in Type 2 Diabetes. *Diabetes Care*. 2023;46(5):918-20.

63. Stanley JR, Clarke ABM, Shulman R, Mahmud FH. Mediating Effects of Technology-Based Therapy on the Relationship Between Socioeconomic Status and Glycemic Management in Pediatric Type 1 Diabetes. *Diabetes Technol Ther*. 2023;25(3):186-93.
64. Agarwal S, Simmonds I, Myers AK. The Use of Diabetes Technology to Address Inequity in Health Outcomes: Limitations and Opportunities. *Current Diabetes Reports*. 2022;22(7):275-81.
65. Appuswamy AV, Desimone ME. Managing Diabetes in Hard to Reach Populations: A Review of Telehealth Interventions. *Current Diabetes Reports*. 2020;20(7):28.

